Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Amphastar's Enox Back, Copaxone Ruling Next Catalyst
MNTA Hot Sheet
Rating Summary:4 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target lowered to $17.00.
Analyst, Ritu Baral, said, "Reiterating rating, reducing target to $17 on reintroduction of Amphastaar generic enox to market and lower revenues to MNTA. Yesterday’s stay on the Amphastar/WPI enox injunction returns the enox market to a multi-player, lower-economics scenario. We expect progress on biosimilars candidates as part of the new Baxter deal over 2012 and 2013. We expect the generic Copaxone suit to resolve in MNTA’s favor mid-2012."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $15.13 yesterday, with a 52 week range of $10.15-$21.00.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Ritu Baral, said, "Reiterating rating, reducing target to $17 on reintroduction of Amphastaar generic enox to market and lower revenues to MNTA. Yesterday’s stay on the Amphastar/WPI enox injunction returns the enox market to a multi-player, lower-economics scenario. We expect progress on biosimilars candidates as part of the new Baxter deal over 2012 and 2013. We expect the generic Copaxone suit to resolve in MNTA’s favor mid-2012."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $15.13 yesterday, with a 52 week range of $10.15-$21.00.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Maintains an 'Equalweight' on Apollo Commercial Real Estate Finance (ARI); Effectively Using Capital, But Shares Trading In-line Vs. Peers
- Barclays Maintains an 'Overweight' on Tidewater (TDW); Dayrates Climb, But Adjusting Numbers Lower on Expenses
- Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
